The stock's rise snapped a four-day losing streak.

Private foundations providing support, resources, and advocacy for individuals and families affected by rare diseases have ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

"Living with kidney disease is a difficult challenge to navigate for patients and their families, and it can feel even more isolating and frustrating when you are living with a rare kidney disease,” ...

Verve Therapeutics remains a high-reward investment despite setbacks. Click here to find out why VERV stock is a Buy.

Vertex Pharmaceuticals (VRTX) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion ...

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

One of the lowest paid CEOs in pharma—and the only woman leading a top-tier giant—is set to receive up to $27.2 million in ...

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

Vertex Pharmaceuticals EVP Edward Atkinson sold 1,767 shares for $849,838 on Feb. 25, 2025. This transaction, conducted under ...